Elron Ventures Ltd · TASE:ELRN
Elron Ventures — Elron Electronic Industries — Investor Presentation (May 2016)
41 slides from Elron Ventures's investor presentation, May 26, 2016
Slide 1: Discover. Innovation
DISCOVER. INNOVATION
Slide 2: Disclaimer and forward-looking statements
This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers. Elron may make improvements and/or changes in the features or content presented
Slide 3: Forward-looking information notice
This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation. *
Slide 4: Discover. Elron
DISCOVER. ELRON
Slide 5: Operational holding company in the VC space
OPERATIONAL HOLDING COMPANY IN THE VC SPACE WE SPECIALIZE IN MEDICAL DEVICE TECHNOLOGIES WITHSIGNIFICANT EXIT POTENTIAL +WE HAVE 50 YEARS EXPERIENCE IDENTIFYING OPPORTUNITIES, BUILDING TECHNOLOGY LEADERS, AND EXITING HOLDINGS +WE INVEST PRIMARILY IN EARLY STAGE COMPANIES +WE RELY ONA PROVEN STRATEGY
Slide 6: Performance in 2016
PERFORMANCE IN 2016: 114 20 59 4 269 * Including RDC * 26
Slide 7: Holdings in companies
1 Includes Elron’s direct holdings and its effective indirect holdings through RDC and RDSeed. Includes investments made after Mar. 31, 2016.2 Includes Elron’s balance and 50.1% of RDC’s balance.3 The above financial data are based on publicly available information and do not represent a valuation,
Slide 8: Discover. BrainsGate
DISCOVER. BRAINSGATE
Slide 9: Our investment: $25M, our holding: 30%
OUR INVESTMENT:$25M OUR HOLDING:30% *
Slide 10: Stroke burden statistics
Sources: American Heart Association: Heart Disease and Stroke Statistics Report – 2015; BrainsGate website: http://brainsgate.com/eng/page.php?id=3&instance_id=9. *
Slide 11: Stroke disability and lifetime cost
Sources: American Heart Association: Heart Disease and Stroke Statistics Report – 2010, 2015; CDC website: http://www.cdc.gov/stroke/facts.htm. mRS Average Lifetime Cost Per Stroke Patient Sources: Samsa et al, Performing Cost-Effectiveness Analysis by Integrating Randomized Trial Data with a Compre
Slide 12: Thrombolysis treatment rates
Source: American Heart Association: Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines–Stroke Hospitals, Schwamm, Circ Cardiovasc Qual Outcomes. 2013;6:543-549. *
Slide 13: Current stroke treatments
CLOT-BUSTING DRUG CLOT RETRIEVING DEVICES ELECTRICAL STIMULATION Sources: Adams HP, et al (2003) Stroke 34, 1056-83; del Zoppo GJ, et al (2009) Stroke 40, 2945-48. *
Slide 14: Stroke treatment trial results
CLOT-BUSTING DRUG CLOT RETRIEVING DEVICES ELECTRICAL STIMULATION Sources: Broderick JP, et al (2013) New England Journal of Medicine 368(10), 893-903; Ciccone A, et al (2013) New England Journal of Medicine 368(10), 904-13; Kidwell CS, et al (2013) New England Journal of Medicine 368(10), 914-23; Be
Slide 15: Electrical stimulation treatment
CLOT-BUSTING DRUG CLOT RETRIEVING DEVICES ELECTRICAL STIMULATION *
Slide 16: BrainsGate ISS system
BrainsGate’s ISS is an investigational device, not approved for marketing. GuideView SPG (sphenopalatine ganglion) = supplies parasympathetic innervation to the anterior cerebral circulation and some of the posterior circulationTransmitter = emits RF waves which energize the implantImplant = deliver
Slide 17: Forward-looking information notice
* This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 18: Discover. Pocared
DISCOVER. POCARED
Slide 19: Our investment: $55M, our holding: 58%
OUR INVESTMENT:$55M OUR HOLDING:58% *
Slide 20: Limits of traditional microbiology testing
Since the 19th century, microbiology testing has been done by culturing bacteria in petri dishes Expensive: Requires reagents and skilled lab techniciansManual: Prone to human error, limited throughputInefficient: Large lab footprintLengthy: Diagnosis that relies on culturing bacteria to reach suffi
Slide 21: Antibiotic resistance
The use of antibiotics is the single most important factor leading to antibiotic resistance around the worldAntibiotics are among the most commonly prescribed drugsUp to 50% of all the antibiotics prescribed are not needed or are not optimally effective as prescribed penicillin 1943 1940 tetracyclin
Slide 22: Diagnostic market sources
Sources: Bourbeau PP and Ledeboer NA (2013) Journal of Microbiology 51(6), 1658-65; Kaplan RL and Burgess TE (2010) Journal of Microbiology & Biology Education 11(2), 140-43; Novak SM and Marlowe EM (2013) Clinics in Laboratory Medicine 33, 567-88. *
Slide 23: P-1000 Analyzer
The Analyzer employs algorithms that determine which wavelength to choose, and detect the organism’s “optical fingerprint” P-1000 Analyzer Sample Processor User interface The P-1000 Analyzer is investigational in the U.S., and CE-marked in the EU. The Sample Processor is exempt from regulatory appro
Slide 24: Forward-looking information notice
* This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 25: Pocared data
Source: Pocared data. * This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 26: Discover. CartiHeal
DISCOVER. CARTIHEAL
Slide 27: Our investment: $12M, our holding: 35%
OUR INVESTMENT:$12M OUR HOLDING:35% *
Slide 28: Cartilage damage and osteoarthritis
* Cartilage does not possess spontaneous healing potential There are no treatments that halt the progression of osteoarthritis (OA) Sources: CDC website: http://www.cdc.gov/arthritis/basics/osteoarthritis.htm, http://www.cdc.gov/nchs/fastats/inpatient-surgery.htm; Losina E, et al (2015) Arthritis Ca
Slide 29: Agili-C results
* 12 weeks post-op 6 weeks post-op 3 weeks post-op The Agili-C is investigational in the U.S., and CE-marked in the EU.
Slide 30: Forward-looking information notice
* This slide contains forward-looking information as defined in Section 21E of the U.S. Securities Exchange Act of 1934, and in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.
Slide 31: Discover. Coramaze
DISCOVER. CORAMAZE
Slide 32: Our investment: €1.75M, our holding: 28%
OUR INVESTMENT:€1.75M OUR HOLDING:28%* * * 28% after the funding round will be completed; currently 17%.
Slide 33: Burden of valvular heart disease
* Sources: Nkomo VT, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006;368: 1005 – 1011; coramaze website: http://www.coramaze.com.
Slide 34: Coramaze system features
ATRAUMATIC ANCHORING IN THE LEFT ATRIUM SPACER THAT ENHANCES LEAFLET COAPTATION PERCUTANEOUS TRANSFEMORAL IMPLANTATION REPOSITIONABLE, DOESN’T INJURE ADJACENT TISSUE PRESERVES NATURAL LEAFLETS, RESTORES THEIR FUNCTIONALITY A SAFE, SIMPLE, AND QUICK IMPLANTATION METHOD Coramaze’s system is an i
Slide 35: Mitral valve acquisitions
ACQUIRER TARGET DEAL SIZE DEVICE STAGE Edwards Lifesciences CardiAQ Valve Technologies up to $400m ($350m upfront + milestone) mitral valve replacement clinical development Abbott Tendyne up to $250m ($225m upfront + milestone) mitral valve replacement clinical development Abbott Cephea Valve Techno
Slide 36: Our investment: $5.9M, our holding: 42%
* OUR INVESTMENT:$5.9M OUR HOLDING:42%
Slide 37: Our investment: $2.9M, our holding: 37%
* OUR INVESTMENT:$2.9M OUR HOLDING:37%
Slide 38: Our investment: $0.75M, our holding: 27%
* OUR INVESTMENT:$0.75M OUR HOLDING:27%* * 27% after the funding round will be completed; currently 16%.
Slide 39: Our investment: $2.5M, our holding: 22%
* OUR INVESTMENT:$2.5M OUR HOLDING:22%
Slide 40: Our investment: $2.2M, our holding: 29%
* OUR INVESTMENT:$2.2M OUR HOLDING:29%
Slide 41: Elron. Opportunity
ELRON. OPPORTUNITY Thank you.
Elron Electronic Industries — Investor Presentation (May 2016) on 6ix